Ursula Wesselmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ursula Wesselmann has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Bill M. Jesdale
Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, USA
4 shared publications - Ian Gilron
Department of Anesthesiology and Perioperative Medicine, Queen's University, Kingston, ON, Canada
4 shared publications - Ulrike Boehmer
Department of Community Health Sciences, Boston University School of Public Health, Boston, Massachusetts
4 shared publications - Caroline F. Pukall
Department of Psychology, Queen’s University, Kingston, ON, Canada
3 shared publications - J. Curtis Nickel
Department of Urology, Queen's University, Kingston, Ontario, Canada
3 shared publications - Keith Jarvi
Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada
3 shared publications
Latest Publications
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Cancer-Related Pain and Sexual Orientation and Gender Identity: An Intersectional Approach
Table S1 shows the unadjusted Odds Ratios of cancer-related pain
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Cancer-Related Pain and Sexual Orientation and Gender Identity: An Intersectional Approach
Table S1 shows the unadjusted Odds Ratios of cancer-related pain
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Data from Cancer-Related Pain and Sexual Orientation and Gender Identity: An Intersectional Approach
Background:We examined cancer-related pain in sexual and gender minorities (SGM) compared with heterosexual cisgender populations and evaluated sociodemographic factors within SGM and heterosexual cisgender cancer survivors. Methods:We combined 2014 to 2023 data of the Behavioral Risk Factor Surveillance System from 23 states and Guam that administered the sexual orientation and gender identity module and the pain-specific cancer survivorship module. Our analytic sample consisted of 56,217 cancer survivors, 1,655 of whom identified as SGM. Results:Sexual minority cancer survivors reported twice or more the prevalence of cancer pain than heterosexual cisgender survivors, with gender minority cancer survivors reporting cancer pain most frequently (28%), followed by sexual minority women (17%), and sexual minority men (14%). Sociodemographic subgroups, consisting of younger, unmarried, not employed, and those with low income, are at increased risk of experiencing cancer pain. Conclusions:Our findings point to heterogeneity among sexual minority cancer survivors’ prevalence of pain and additional efforts to characterize gender minorities’ disparities in cancer pain. Impact:There is an urgent need for evidence-based real-life clinical data characterization of SGM cancer pain disparities and efforts to reduce their cancer-related pain.See related In the Spotlight, p. 1236
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Cancer-Related Pain and Sexual Orientation and Gender Identity: An Intersectional Approach
Background:We examined cancer-related pain in sexual and gender minorities (SGM) compared with heterosexual cisgender populations and evaluated sociodemographic factors within SGM and heterosexual cisgender cancer survivors. Methods:We combined 2014 to 2023 data of the Behavioral Risk Factor Surveillance System from 23 states and Guam that administered the sexual orientation and gender identity module and the pain-specific cancer survivorship module. Our analytic sample consisted of 56,217 cancer survivors, 1,655 of whom identified as SGM. Results:Sexual minority cancer survivors reported twice or more the prevalence of cancer pain than heterosexual cisgender survivors, with gender minority cancer survivors reporting cancer pain most frequently (28%), followed by sexual minority women (17%), and sexual minority men (14%). Sociodemographic subgroups, consisting of younger, unmarried, not employed, and those with low income, are at increased risk of experiencing cancer pain. Conclusions:Our findings point to heterogeneity among sexual minority cancer survivors’ prevalence of pain and additional efforts to characterize gender minorities’ disparities in cancer pain. Impact:There is an urgent need for evidence-based real-life clinical data characterization of SGM cancer pain disparities and efforts to reduce their cancer-related pain.See related In the Spotlight, p. 1236
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Cancer-Related Pain and Sexual Orientation and Gender Identity: An Intersectional Approach
Table S2 shows frequencies and unadjusted Odds Ratios of uncontrolled pain
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Cancer-Related Pain and Sexual Orientation and Gender Identity: An Intersectional Approach
Table S2 shows frequencies and unadjusted Odds Ratios of uncontrolled pain
- 26 March 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (8) , OF1-OF8
Cancer-Related Pain and Sexual Orientation and Gender Identity: An Intersectional Approach
Background: We examined cancer-related pain in sexual and gender minorities (SGM) compared with heterosexual cisgender populations and evaluated sociodemographic factors within SGM and heterosexual cisgender cancer survivors. Methods: We combined 2014 to 2023 data of the Behavioral Risk Factor Surveillance System from 23 states and Guam that administered the sexual orientation and gender identity module and the pain-specific cancer survivorship module. Our analytic sample consisted of 56,217 cancer survivors, 1,655 of whom identified as SGM. Results: Sexual minority cancer survivors reported twice or more the prevalence of cancer pain than heterosexual cisgender survivors, with gender minority cancer survivors reporting cancer pain most frequently (28%), followed by sexual minority women (17%), and sexual minority men (14%). Sociodemographic subgroups, consisting of younger, unmarried, not employed, and those with low income, are at increased risk of experiencing cancer pain. Conclusions: Our findings point to heterogeneity among sexual minority cancer survivors’ prevalence of pain and additional efforts to characterize gender minorities’ disparities in cancer pain. Impact: There is an urgent need for evidence-based real-life clinical data characterization of SGM cancer pain disparities and efforts to reduce their cancer-related pain.
- 26 March 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (8) , OF1-OF8
Cancer-Related Pain and Sexual Orientation and Gender Identity: An Intersectional Approach
Background: We examined cancer-related pain in sexual and gender minorities (SGM) compared with heterosexual cisgender populations and evaluated sociodemographic factors within SGM and heterosexual cisgender cancer survivors. Methods: We combined 2014 to 2023 data of the Behavioral Risk Factor Surveillance System from 23 states and Guam that administered the sexual orientation and gender identity module and the pain-specific cancer survivorship module. Our analytic sample consisted of 56,217 cancer survivors, 1,655 of whom identified as SGM. Results: Sexual minority cancer survivors reported twice or more the prevalence of cancer pain than heterosexual cisgender survivors, with gender minority cancer survivors reporting cancer pain most frequently (28%), followed by sexual minority women (17%), and sexual minority men (14%). Sociodemographic subgroups, consisting of younger, unmarried, not employed, and those with low income, are at increased risk of experiencing cancer pain. Conclusions: Our findings point to heterogeneity among sexual minority cancer survivors’ prevalence of pain and additional efforts to characterize gender minorities’ disparities in cancer pain. Impact: There is an urgent need for evidence-based real-life clinical data characterization of SGM cancer pain disparities and efforts to reduce their cancer-related pain.
- Open Access
- 13 June 2025
- Published by Wolters Kluwer Health in Pain Reports
- Vol. 10 (4) , e1299
Efficacy and safety of drug combinations for chronic pelvic pain: a systematic review
Clinical disorders associated with chronic pelvic pain (CPP) cause demonstrable emotional and physical dysfunction as well as increased health care utilization. Interventions that have been studied for the treatment of CPP often provide inadequate relief and/or intolerable adverse effects. The common practice of combining multiple CPP treatments needs more supportive evidence, and emerging combination trials have been evaluated in this systematic review. We searched MEDLINE and EMBASE and CENTRAL databases for CPP combination trials. This review included double-blind randomized controlled trials comparing combinations of 2 or more agents to at least 1 monotherapy in adults with CPP. The primary outcome was reduction in pain intensity or pain relief, and secondary outcomes included adverse events, quality of life, and other symptoms. Risk of bias was assessed. Nine studies (1,299 participants) were included and involved various different treatments including ciprofloxacin, tamsulosin, pentosan polysulfate, hyaluronic acid, chondroitin, hydroxyzine, troxerutin, carbazochrome, linzagolix, and allopurinol. Studies were heterogenous according to several features including studied treatments, dose and route of administration, and underlying condition such that no studies could be combined for meta-analysis. None of the included studies reported a significant difference in reducing pain intensity for combination therapy vs monotherapy. If future proof-of-concept studies demonstrate that a given combination is superior to all monotherapy components, subsequent large, double-blind randomized, controlled clinical trials of such combinations for CPP are required to better elucidate the role of combination therapy in clinical settings.
- 13 June 2025
- Published by Wolters Kluwer Health in Pain Reports
- Vol. 10 (4) , e1299
Open AccessEfficacy and safety of drug combinations for chronic pelvic pain: a systematic review
Clinical disorders associated with chronic pelvic pain (CPP) cause demonstrable emotional and physical dysfunction as well as increased health care utilization. Interventions that have been studied for the treatment of CPP often provide inadequate relief and/or intolerable adverse effects. The common practice of combining multiple CPP treatments needs more supportive evidence, and emerging combination trials have been evaluated in this systematic review. We searched MEDLINE and EMBASE and CENTRAL databases for CPP combination trials. This review included double-blind randomized controlled trials comparing combinations of 2 or more agents to at least 1 monotherapy in adults with CPP. The primary outcome was reduction in pain intensity or pain relief, and secondary outcomes included adverse events, quality of life, and other symptoms. Risk of bias was assessed. Nine studies (1,299 participants) were included and involved various different treatments including ciprofloxacin, tamsulosin, pentosan polysulfate, hyaluronic acid, chondroitin, hydroxyzine, troxerutin, carbazochrome, linzagolix, and allopurinol. Studies were heterogenous according to several features including studied treatments, dose and route of administration, and underlying condition such that no studies could be combined for meta-analysis. None of the included studies reported a significant difference in reducing pain intensity for combination therapy vs monotherapy. If future proof-of-concept studies demonstrate that a given combination is superior to all monotherapy components, subsequent large, double-blind randomized, controlled clinical trials of such combinations for CPP are required to better elucidate the role of combination therapy in clinical settings.
- Top Cited PapersOpen Access
- 2 October 2022
- Published by Elsevier in The Journal of Pain
- Vol. 24 (2) , 204-225
Optimizing and Accelerating the Development of Precision Pain Treatments for Chronic Pain: IMMPACT Review and Recommendations
- 2 October 2022
- Published by Elsevier in The Journal of Pain
- Vol. 24 (2) , 204-225
Top Cited PapersOpen AccessOptimizing and Accelerating the Development of Precision Pain Treatments for Chronic Pain: IMMPACT Review and Recommendations
- Open Access
- 17 May 2021
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 10 (5) , e21909
Efficacy and Safety of Drug Combinations for Chronic Pelvic Pain: Protocol for a Systematic Review
Background: Chronic pelvic pain with various etiologies and mechanisms affects men and women and is a major challenge. Monotherapy is often unsuccessful for chronic pelvic pain, and combinations of different classes of medications are frequently prescribed, with the expectation of improved outcomes. Although a number of combination trials for chronic pelvic pain have been reported, we are not aware of any systematic reviews of the available evidence on combination drug therapy for chronic pelvic pain. Objective: We have developed a protocol for a systematic review to evaluate available evidence of the efficacy and safety of drug combinations for chronic pelvic pain. Methods: This systematic review will involve a detailed search of randomized controlled trials investigating drug combinations to treat chronic pelvic pain in adults. The databases searched will include the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and EMBASE from their inception until the date the searches are run to identify relevant studies. The primary outcome will be pain relief measured using validated scoring tools. Secondary outcomes, where reported, will include the following: adverse events, serious adverse events, sexual function, quality of life, and depression and anxiety. Methodological quality of each included study will be assessed using the Cochrane Risk of Bias Tool. Results: The systematic review defined by this protocol is expected to synthesize available good quality evidence on combination drug therapy in chronic pelvic pain, which may help guide future research and treatment choices for patients and their health care providers. Conclusions: This review will provide a clearer understanding of the efficacy and safety of combination pharmacological therapy for chronic pelvic pain. Trial Registration: PROSPERO International Prospective Register of Systematic Reviews CRD42020192231; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=192231 International Registered Report Identifier (IRRID): PRR1-10.2196/21909
- 17 May 2021
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 10 (5) , e21909
Open AccessEfficacy and Safety of Drug Combinations for Chronic Pelvic Pain: Protocol for a Systematic Review
Background: Chronic pelvic pain with various etiologies and mechanisms affects men and women and is a major challenge. Monotherapy is often unsuccessful for chronic pelvic pain, and combinations of different classes of medications are frequently prescribed, with the expectation of improved outcomes. Although a number of combination trials for chronic pelvic pain have been reported, we are not aware of any systematic reviews of the available evidence on combination drug therapy for chronic pelvic pain. Objective: We have developed a protocol for a systematic review to evaluate available evidence of the efficacy and safety of drug combinations for chronic pelvic pain. Methods: This systematic review will involve a detailed search of randomized controlled trials investigating drug combinations to treat chronic pelvic pain in adults. The databases searched will include the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and EMBASE from their inception until the date the searches are run to identify relevant studies. The primary outcome will be pain relief measured using validated scoring tools. Secondary outcomes, where reported, will include the following: adverse events, serious adverse events, sexual function, quality of life, and depression and anxiety. Methodological quality of each included study will be assessed using the Cochrane Risk of Bias Tool. Results: The systematic review defined by this protocol is expected to synthesize available good quality evidence on combination drug therapy in chronic pelvic pain, which may help guide future research and treatment choices for patients and their health care providers. Conclusions: This review will provide a clearer understanding of the efficacy and safety of combination pharmacological therapy for chronic pelvic pain. Trial Registration: PROSPERO International Prospective Register of Systematic Reviews CRD42020192231; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=192231 International Registered Report Identifier (IRRID): PRR1-10.2196/21909
- 19 March 2021
- Published by Springer Nature in Die Dermatologie
- Vol. 72 (10) , 922-924
Therapierefraktäre ulzeröse Plaque am Penis
- 19 March 2021
- Published by Springer Nature in Die Dermatologie
- Vol. 72 (10) , 922-924
Therapierefraktäre ulzeröse Plaque am Penis
- Open Access
- 28 June 2020
- Published by JMIR Publications Inc. in JMIR Preprints
Efficacy and Safety of Drug Combinations for Chronic Pelvic Pain: Protocol for a Systematic Review (Preprint)
BACKGROUND Chronic pelvic pain with various etiologies and mechanisms affects men and women and is a major challenge. Monotherapy is often unsuccessful for chronic pelvic pain, and combinations of different classes of medications are frequently prescribed, with the expectation of improved outcomes. Although a number of combination trials for chronic pelvic pain have been reported, we are not aware of any systematic reviews of the available evidence on combination drug therapy for chronic pelvic pain. OBJECTIVE We have developed a protocol for a systematic review to evaluate available evidence of the efficacy and safety of drug combinations for chronic pelvic pain. METHODS This systematic review will involve a detailed search of randomized controlled trials investigating drug combinations to treat chronic pelvic pain in adults. The databases searched will include the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and EMBASE from their inception until the date the searches are run to identify relevant studies. The primary outcome will be pain relief measured using validated scoring tools. Secondary outcomes, where reported, will include the following: adverse events, serious adverse events, sexual function, quality of life, and depression and anxiety. Methodological quality of each included study will be assessed using the Cochrane Risk of Bias Tool. RESULTS The systematic review defined by this protocol is expected to synthesize available good quality evidence on combination drug therapy in chronic pelvic pain, which may help guide future research and treatment choices for patients and their health care providers. CONCLUSIONS This review will provide a clearer understanding of the efficacy and safety of combination pharmacological therapy for chronic pelvic pain. CLINICALTRIAL PROSPERO International Prospective Register of Systematic Reviews CRD42020192231; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=192231 INTERNATIONAL REGISTERED REPORT PRR1-10.2196/21909
- 28 June 2020
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessEfficacy and Safety of Drug Combinations for Chronic Pelvic Pain: Protocol for a Systematic Review (Preprint)
BACKGROUND Chronic pelvic pain with various etiologies and mechanisms affects men and women and is a major challenge. Monotherapy is often unsuccessful for chronic pelvic pain, and combinations of different classes of medications are frequently prescribed, with the expectation of improved outcomes. Although a number of combination trials for chronic pelvic pain have been reported, we are not aware of any systematic reviews of the available evidence on combination drug therapy for chronic pelvic pain. OBJECTIVE We have developed a protocol for a systematic review to evaluate available evidence of the efficacy and safety of drug combinations for chronic pelvic pain. METHODS This systematic review will involve a detailed search of randomized controlled trials investigating drug combinations to treat chronic pelvic pain in adults. The databases searched will include the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and EMBASE from their inception until the date the searches are run to identify relevant studies. The primary outcome will be pain relief measured using validated scoring tools. Secondary outcomes, where reported, will include the following: adverse events, serious adverse events, sexual function, quality of life, and depression and anxiety. Methodological quality of each included study will be assessed using the Cochrane Risk of Bias Tool. RESULTS The systematic review defined by this protocol is expected to synthesize available good quality evidence on combination drug therapy in chronic pelvic pain, which may help guide future research and treatment choices for patients and their health care providers. CONCLUSIONS This review will provide a clearer understanding of the efficacy and safety of combination pharmacological therapy for chronic pelvic pain. CLINICALTRIAL PROSPERO International Prospective Register of Systematic Reviews CRD42020192231; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=192231 INTERNATIONAL REGISTERED REPORT PRR1-10.2196/21909